Beyond Next Ventures

Beyond Next Ventures is a Japanese venture capital firm established in August 2014, dedicated to fostering innovation in deep tech. The firm's core mission is to create a better future by partnering with exceptional researchers and entrepreneurs who are tackling global challenges. They achieve this by building a comprehensive ecosystem that supports the commercialization of promising research from academia and large corporations, primarily focusing on deep tech scientific innovations.

The firm provides continuous financial support to top entrepreneurs, typically investing at the Seed stage and extending through to later growth stages. Beyond Next Ventures also offers extensive incubation support, including executive candidate matching, team building, business plan development, financial assistance for grant funding, and access to incubation wet lab facilities. Their accelerator program, BRAVE, has supported over 200 innovators, and the "INNOVATION LEADERS PROGRAM" has nurtured the careers of over 450 individuals in deep tech startups.

Beyond Next Ventures manages approximately $300 million USD in assets, with its latest fund, BNV Fund – 3, closing at 25.7 billion yen. The firm has a notable portfolio with successful exits, including IPOs for SUSMED, Inc. and QD Laser, Inc., and M&As for companies like Repetoire Genesis, Inc. and GigIndia. Recent investments include Visban, GramEye, and FinalLayer. Their investment focus spans critical sectors such as healthcare, climate technology, agri-food, and artificial intelligence, with a strong presence in both Japan and India.

The team at Beyond Next Ventures comprises experienced professionals, including Founder CEO Tsuyoshi Ito, Managing Director Kengo Ueha, and Partners Akito Arima, Masaya Eshita, Shota Sagiyama, Jay Krishnan, and Katsuya Hashizume. The team's diverse expertise, including individuals with backgrounds in medical device development, intellectual property, and audit, enables them to provide hands-on support and strategic guidance to their portfolio companies, helping them navigate the journey from lab to market.